Search results
Results from the WOW.Com Content Network
Lawsuits over Xarelto began piling up in 2014 and the companies had so far won all six trials over Xarelto's alleged bleeding risk. Bayer, J&J settle thousands of U.S. Xarelto lawsuits for $775 ...
GSK on Wednesday said it agreed to settle another lawsuit in California alleging its discontinued heartburn drug Zantac caused cancer, as the British drugmaker sought to end costly litigation that ...
The drugmaker has settled a series of lawsuits related to Zantac over the past 12 months, including several in California. California is generally seen as a more challenging legal environment for ...
The following are settlements reached with US authorities against pharmaceutical companies to resolve allegations of "off-label" promotion of drugs. Under the Federal Food, Drug, and Cosmetic Act, it is illegal for pharmaceutical companies to promote their products for uses not approved by the Food and Drug Administration (FDA), and corporations that market drugs for off-label indications may ...
The following is a list of the 20 largest settlements reached between the United States Department of Justice and pharmaceutical companies from 2001 to 2013, ordered by the size of the total settlement. The settlement amount includes both the civil (False Claims Act) settlement and criminal fine.
The following is a list of the 21 largest civil settlements, reached between the United States Department of Justice and pharmaceutical companies from 2001 to 2017, ordered by the size of the total civil settlement. Some of these matters also resolved criminal fines and penalties, listed in parentheses, but these amounts are not considered when ...
Bayer. $10.9 billion German pharmaceutical company Bayer agreed to pay nearly $11 billion to settle thousands of lawsuits over subsidiary Monsanto’s weed-killer Roundup. The settlement aims to ...
In 2019, Bayer and Johnson & Johnson (who market Xarelto together) settled around 25,000 lawsuits on the blood thinning drug Xarelto (rivaroxaban) by agreeing to disburse $775 million (US) to federal and state plaintiffs who said the companies had not properly warned patients about possible fatal bleeding as a result of ingesting the drug ...